Comments by Alex H. Moss, Executive Director of the Public Interest Patent Law Institute on the need for a statement and action from the Federal Trade Commission to put a stop to an unfair method of competition: improperly listing patents in the Orange Book to deter generic drug competition that is necessary to bring down drug prices.